Aimmune presents new biennial treatment satisfaction data for patients with peanut allergy at EAACI Hybrid Annual Congress 2021

News and research before you hear about it on CNBC and others. Request your one-week free trial of StreetInsider Premium here.

– Two years of PALFORZIA® ▼ [defatted powder of Arachis hypogaea L., semen (peanuts)] Data shows that patients report that treatment is convenient and easy

– Additional poster with preliminary findings on longer-term safety results from the ongoing phase 3 study ARC008 will be presented –

LONDON – (BUSINESS WIRE) – Aimmune Therapeutics UK Ltd., a Nestlé Health Science company that develops and markets pharmaceutical therapies for the prevention, treatment and treatment of diet and metabolic diseases, announced today that it has new data on the Immunotherapy PALFORZIA will present treatment satisfaction for its oral medication at the Hybrid Congress 2021 of the European Academy of Allergy and Clinical Immunology (EAACI) in Poland. The company will publish updated treatment satisfaction data from its Phase 3 randomized, double-blind, placebo-controlled PALISADE study and the ARC004 open-label follow-up study.

Patient-reported treatment satisfaction was assessed over a period of two years after daily treatment with PALFORZIA in a clinical trial setting using the Medication Treatment Satisfaction Questionnaire (TSQM-9). Participants with peanut allergy reported overall satisfaction with the effectiveness and convenient items, as well as the drug’s ability to treat their condition.

“Patient focus is a key pillar of clinical development and we look forward to presenting this encouraging patient satisfaction data,” said Andrew Oxtoby, president and chief executive officer of Aimmune Therapeutics. “We know that efficacy and safety remain the traditional, critical endpoints assessed; However, true clinical and medical advancement requires a deep understanding of the patient experience – what the patient values ​​and needs for a positive outcome. ”

Additional data to be presented at EAACI include an update on the ongoing, open-label phase 3 study ARC008, which is investigating longer-term safety in patients. The data collected from this study will help facilitate discussions about longer term safety with clinicians, peanut allergy sufferers, and their families.

Full details of the oral and poster presentations can be found below.

Oral presentation

Title: Treatment satisfaction with continued oral immunotherapy for peanut allergy: results after 1, 1.5 and 2 years of daily therapy

Presenter: Katharina Blümchen, MD, University Hospital Frankfurt (Germany)

Session title: OAS 01 New perspectives in allergen immunotherapy

Date / Time: July 10th, 3: 05-3: 13pm CEST

Poster presentation

Title: Longer-Term Safety Results of Defatted Powder of Arachis hypogaea L. semen (Peanuts) in Subjects from Previous Clinical Studies (ARC008): an ongoing study and preliminary findings

Poster: 247

Moderation: Kirsten Beyer, MD, Charité University Hospital (Germany)

Session title: ePoster Allergen Immunotherapy

Date / Time: July 10th, 9 am-8.30pm CEST


PALFORZIA was approved by the European Commission (EC) in December 2020 for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy associated with a peanut-avoiding diet. PALFORZIA can be continued in patients over 18 years of age.

PALFORZIA is a complex biological drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. In OIT, the specific allergenic proteins are initially absorbed in very small amounts, followed by incrementally increasing amounts, which can lead to allergic reactions to the allergen being weakened over time. PALFORZIA is a consistently developed OIT in pharmaceutical quality for peanut allergy with a precisely defined allergen profile to ensure the consistency of each dose from 0.5 mg (corresponds to about 1/600 of a peanut kernel) to 300 mg.

PALFORZIA is not intended for immediate relief of allergy symptoms and does not provide immediate relief. Therefore, this medicine must not be used for the emergency treatment of allergic reactions, including anaphylaxis. Self-injectable adrenaline (epinephrine) must be available to the patient at all times.

A full summary of product features can be found at

About Aimmune

Aimmune Therapeutics UK Ltd., a Nestlé Health Science company, is a biopharmaceutical company that develops and markets pharmaceutical therapies for the prevention, treatment and treatment of diet and metabolic disorders. More information is available at

About Nestlé Health Science

Nestlé Health Science (NHSc), a wholly-owned subsidiary of Nestlé, is a globally recognized leader in nutritional science. At NHSc, we are committed to enabling healthier lives through nutrition for consumers, patients and their healthcare partners. We offer a comprehensive consumer health portfolio with industry leading medical nutrition, consumer and vitamins, minerals and nutritional supplements (VMS) brands that are science-based solutions that cover every facet of health from prevention to maintenance to treatment. NHSc is redefining the way we approach health management in several key areas such as pediatric health, allergy, acute care, oncology, metabolic health, healthy aging, gastrointestinal health and congenital metabolic disorders. Headquartered in Switzerland, NHSc employs over 5,000 people around the world who are committed to changing people’s lives for healthier today and tomorrow.

Europe Media:

Jemini Sedani

+44 7940 594788

Source: Aimmune Therapeutics UK Ltd.

Related Articles